Researchers found that a new cancer treatment called REVTORPYK™ (gedatolisib) has been approved by the FDA for certain types of breast cancer. This drug, when used with fulvestrant and possibly palbociclib, is now recommended as a preferred option for patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer who have not responded to prior endocrine therapy. This approval is significant as REVTORPYK is the first of its kind to target specific cancer pathways, potentially offering new hope for patients facing limited treatment options.

This development matters for your health because it could lead to better outcomes for individuals battling advanced breast cancer. In clinical trials, patients receiving REVTORPYK in combination with fulvestrant and palbociclib experienced a median progression-free survival (PFS) of 9.3 months, compared to just 2.0 months with fulvestrant alone. This represents a substantial improvement, giving patients more time without disease progression. The objective response rate was also notable, with 32% of patients responding positively to the combination treatment.

The evidence supporting REVTORPYK comes from the Phase 3 VIKTORIA-1 trial, which included a global cohort of patients. While the results are promising, it’s important to note that they are based on early-stage clinical trials. As such, while the findings are encouraging, further research is needed to confirm long-term effectiveness and safety in broader populations. The drug is expected to be commercially available in the U.S. by late 2026, with options for eligible patients to access it sooner through an expanded access program.

For more details, see the original announcement from GlobeNewswire.